MDT-AP-3042
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 12.1
- sex
- F
- new_clusters
- C4
- umap1_2d
- 4.280792346
- umap2_2d
- 4.403661537
- umap1_3d
- 2.017551859
- umap2_3d
- -1.788068569
- umap3_3d
- -3.192295879
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.520
- MYC_TARGETS_V1+0.350
- OXIDATIVE_PHOSPHORYLATION+0.350
- PROTEIN_SECRETION+0.350
- MITOTIC_SPINDLE+0.310
- DNA_REPAIR+0.290
- ADIPOGENESIS+0.260
- MTORC1_SIGNALING+0.230
- HEME_METABOLISM+0.210
Top 10 suppressed
- NOTCH_SIGNALING-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- KRAS_SIGNALING_DN-0.300
- TNFA_SIGNALING_VIA_NFKB-0.290
- HEDGEHOG_SIGNALING-0.280
- CHOLESTEROL_HOMEOSTASIS-0.270
- ANGIOGENESIS-0.260
- MYOGENESIS-0.260
- UV_RESPONSE_DN-0.250
- BILE_ACID_METABOLISM-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclc239860_S81.txt | — | cohortSC | 0.822 |
| 2 | MDT-AP-2755 | Med | Medulloblastoma | 0.815 |
| 3 | TCGA-A8-A081-01A-11R-A00Z-07 | — | C | 0.810 |
| 4 | TCGA-C8-A1HN-01A-11R-A137-07 | — | B | 0.810 |
| 5 | BS_HF3RNN2T | Med | Medulloblastoma | 0.807 |
| 6 | BS_MB7WN0ZB | Embryonal tumors | — | 0.805 |
| 7 | MDT-AP-0415 | Med | Medulloblastoma | 0.793 |
| 8 | TCGA-E2-A15A-06A-11R-A12D-07 | — | B | 0.790 |
| 9 | 57ab4aef-e740-4494-b0b5-3b008f9d446f | — | — | 0.790 |
| 10 | TCGA-BH-A18R-01A-11R-A12D-07 | — | C | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |